NCT04398485View on ClinicalTrials.gov

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

ION251

ION251 administered by IV infusion

Trial Locations (6)

28204

Levine Cancer Institute, Charlotte

48201

Barbara Ann Karmanos Cancer Institute, Detroit

63130

Washington University School of Medicine in Saint Louis, St Louis

90048

Cedars-Sinai Medical Center, Los Angeles

90095

UCLA Rrmc, Los Angeles

92093

University of California San Diego Moores Cancer Center, La Jolla

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY